2020
DOI: 10.1002/jgh3.12465
|View full text |Cite
|
Sign up to set email alerts
|

Association of metabolic‐associated fatty liver disease and risk of severe coronavirus disease 2019 illness

Abstract: Given the global health burden caused by the Coronavirus Disease 2019 (COVID-19), there have been numerous studies aimed to understand its clinical course and to determine risk factors that may impact prognosis. Pre-existing medical conditions are linked with COVID-19 severity, particularly cardiometabolic diseases. Increasing evidence has also linked metabolic-associated fatty liver disease (MAFLD) with severe COVID-19 illness. Thus, we review different published clinical data relating to the association of M… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1
1

Citation Types

1
8
0

Year Published

2021
2021
2023
2023

Publication Types

Select...
5
1

Relationship

0
6

Authors

Journals

citations
Cited by 7 publications
(9 citation statements)
references
References 29 publications
1
8
0
Order By: Relevance
“…This trend was valid even after adjusting for age, sex, and underlying disease. This is consistent with recent findings from previous studies in which the proportion of severe COVID-19 cases was higher in patients with MAFLD [ 31 ]. The risk was reported to have a wide range of OR (1.10 to 31.2), and this variability among studies is probably attributed to the different study designs, prevalence of COVID-19, quarantine strategies, and definitions of MAFLD or NAFLD/NASH.…”
Section: Discussionsupporting
confidence: 94%
“…This trend was valid even after adjusting for age, sex, and underlying disease. This is consistent with recent findings from previous studies in which the proportion of severe COVID-19 cases was higher in patients with MAFLD [ 31 ]. The risk was reported to have a wide range of OR (1.10 to 31.2), and this variability among studies is probably attributed to the different study designs, prevalence of COVID-19, quarantine strategies, and definitions of MAFLD or NAFLD/NASH.…”
Section: Discussionsupporting
confidence: 94%
“…MAFLD patients had a higher likelihood of abnormal liver biochemistries, higher risk of respiratory disease progression, more liver injury during hospitalization and a higher viral shedding time 34,35 . A recent systematic literature review supports the hypothesis that the presence of metabolic dysfunction‐associated fatty liver disease (MAFLD) 32 may represent a risk factor for symptomatic, severe and progressive COVID‐19 16,33,34,36‐44 . (Table 1).…”
Section: Introductionmentioning
confidence: 83%
“…34,35 A recent systematic literature review supports the hypothesis that the presence of metabolic dysfunction-associated fatty liver disease (MAFLD) 32 may represent a risk factor for symptomatic, severe and progressive COVID-19. 16,33,34,[36][37][38][39][40][41][42][43][44] (Table 1).…”
Section: Impact Of Mafld On Outcomes Of Covid-19 Patientsmentioning
confidence: 99%
“…MAFLD is diagnosed by evidence of hepatic steatosis and one of the following three criteria: overweight or obesity; type 2 diabetes mellitus; or metabolic dysregulation. Obesity is of greater risk for respiratory infection factors, and diabetes mellitus patients have a three-fold increased risk of developing critical illness[ 48 , 49 ]. The duration of viral shedding was reported to be longer in COVID-19 patients with MAFLD (12.1 d) than in those without MAFLD (5.4 d)[ 48 ].…”
Section: Liver Dysfunction In Liver Disease Concomitant With Covid-19 Infectionmentioning
confidence: 99%